Confidential Drugmaker Deals Could Cut Projected Medicare Savings from Most-Favored-Nation Pricing by 71% to Nearly 80%

Confidential Drugmaker Deals Could Cut Projected Medicare Savings from Most-Favored-Nation Pricing by 71% to Nearly 80%

A Lancet model says confidential drugmaker deals could erase 71% to nearly 80% of projected Medicare savings from foreign drug price benchmarks.

What Do the New MFN Deals Lock In?

Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.